Drug Shortage Report for LEVOTHYROXINE SODIUM FOR INJECTION
Report ID | 187645 |
Drug Identification Number | 02245948 |
Brand name | LEVOTHYROXINE SODIUM FOR INJECTION |
Common or Proper name | LEVOTHYROXINE SODIUM FOR INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | LEVOTHYROXINE SODIUM |
Strength(s) | 500MCG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 10mL |
ATC code | H03AA |
ATC description | THYROID PREPARATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2023-03-31 |
Actual start date | 2023-03-31 |
Estimated end date | 2023-06-15 |
Actual end date | 2023-06-16 |
Shortage status | Resolved |
Updated date | 2023-07-20 |
Company comments | Levothyroxine Sodium Injection 100 mcg/mL SD Vial 5 mL is available for substitution. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2023-07-20 | French | Compare |
v4 | 2023-07-20 | English | Compare |
v3 | 2023-04-01 | English | Compare |
v2 | 2023-03-22 | French | Compare |
v1 | 2023-03-22 | English | Compare |
Showing 1 to 5 of 5